Simone U. Dalm

1.3k total citations
42 papers, 967 citations indexed

About

Simone U. Dalm is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Epidemiology. According to data from OpenAlex, Simone U. Dalm has authored 42 papers receiving a total of 967 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 24 papers in Radiology, Nuclear Medicine and Imaging and 17 papers in Epidemiology. Recurrent topics in Simone U. Dalm's work include Radiopharmaceutical Chemistry and Applications (23 papers), Peptidase Inhibition and Analysis (18 papers) and Neuroendocrine Tumor Research Advances (17 papers). Simone U. Dalm is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (23 papers), Peptidase Inhibition and Analysis (18 papers) and Neuroendocrine Tumor Research Advances (17 papers). Simone U. Dalm collaborates with scholars based in Netherlands, Greece and Canada. Simone U. Dalm's co-authors include Marion de Jong, Erik de Blois, Mark Konijnenberg, Gabriela N. Doeswijk, Θεοδοσία Μάινα, Berthold A. Nock, Yann Seimbille, Dik C. van Gent, Julie Nonnekens and Wytske M. van Weerden and has published in prestigious journals such as PLoS ONE, International Journal of Molecular Sciences and Journal of Controlled Release.

In The Last Decade

Simone U. Dalm

40 papers receiving 959 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Simone U. Dalm Netherlands 19 549 496 361 230 151 42 967
A. Srinivasan United States 13 610 1.1× 608 1.2× 631 1.7× 140 0.6× 122 0.8× 20 1.1k
Maria‐Luisa Tamma Switzerland 12 356 0.6× 379 0.8× 284 0.8× 126 0.5× 117 0.8× 14 641
Mihaela Ginj Switzerland 14 931 1.7× 837 1.7× 1.1k 3.0× 176 0.8× 260 1.7× 21 1.7k
Erik Parker United States 15 294 0.5× 141 0.3× 221 0.6× 438 1.9× 272 1.8× 31 1.1k
Shaobo Yao China 19 692 1.3× 311 0.6× 325 0.9× 78 0.3× 199 1.3× 60 1.2k
Jörg Schmitt Switzerland 8 807 1.5× 623 1.3× 1.0k 2.8× 99 0.4× 119 0.8× 10 1.4k
Thorsten Poethko Germany 16 266 0.5× 847 1.7× 160 0.4× 99 0.4× 247 1.6× 21 1.2k
Buddy Setyono-Han Netherlands 16 396 0.7× 220 0.4× 339 0.9× 99 0.4× 337 2.2× 23 994
Aurélie Prignon France 15 202 0.4× 135 0.3× 106 0.3× 83 0.4× 249 1.6× 25 647
Zohreh Varasteh Sweden 21 610 1.1× 727 1.5× 112 0.3× 225 1.0× 310 2.1× 42 1.2k

Countries citing papers authored by Simone U. Dalm

Since Specialization
Citations

This map shows the geographic impact of Simone U. Dalm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simone U. Dalm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simone U. Dalm more than expected).

Fields of papers citing papers by Simone U. Dalm

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simone U. Dalm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simone U. Dalm. The network helps show where Simone U. Dalm may publish in the future.

Co-authorship network of co-authors of Simone U. Dalm

This figure shows the co-authorship network connecting the top 25 collaborators of Simone U. Dalm. A scholar is included among the top collaborators of Simone U. Dalm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simone U. Dalm. Simone U. Dalm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stuurman, Debra, et al.. (2025). Chemotherapy alters radiosensitivity and GRPR expression of prostate and breast cancer cells. EJNMMI Research. 15(1). 98–98.
2.
Morgat, Clément, Heying Duan, Simone U. Dalm, et al.. (2025). A Vision for Gastrin-Releasing Peptide Receptor Targeting for Imaging and Therapy: Perspective from Academia and Industry. Journal of Nuclear Medicine. 66(8). 1160–1167. 2 indexed citations
3.
Doukas, Michail, et al.. (2025). Illuminating radionuclide therapy response: Monitoring cancer cell and CAF survival in a direct 2D co-culture model. Nuclear Medicine and Biology. 150-151. 109571–109571.
4.
Dalm, Simone U., et al.. (2025). Exploring the landscape of current in vitro and in vivo models and their relevance for targeted radionuclide theranostics. European Journal of Nuclear Medicine and Molecular Imaging. 52(9). 3291–3311. 2 indexed citations
5.
Haeck, Joost, et al.. (2023). The Balance Between the Therapeutic Efficacy and Safety of [177Lu]Lu-NeoB in a Preclinical Prostate Cancer Model. Molecular Imaging and Biology. 26(1). 114–123. 7 indexed citations
6.
Leenders, Geert J.L.H. van, et al.. (2023). GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches. Frontiers in Oncology. 13. 1199432–1199432. 14 indexed citations
7.
Stuurman, Debra, et al.. (2023). Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting. European Journal of Nuclear Medicine and Molecular Imaging. 50(13). 3851–3861. 11 indexed citations
8.
Stuurman, Debra, et al.. (2023). Synthesis and Evaluation of ePSMA-DM1: A New Theranostic Small-Molecule Drug Conjugate (T-SMDC) for Prostate Cancer. Pharmaceuticals. 16(8). 1072–1072. 7 indexed citations
9.
Koetsveld, Peter M. van, Corrina M.A. de Ridder, Debra Stuurman, et al.. (2023). Applying HDACis to increase SSTR2 expression and radiolabeled DOTA-TATE uptake: from cells to mice. Life Sciences. 334. 122173–122173. 1 indexed citations
10.
Konijnenberg, Mark, Erik de Blois, Corrina M.A. de Ridder, et al.. (2022). Safety of [177Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity. European Journal of Nuclear Medicine and Molecular Imaging. 49(13). 4440–4451. 23 indexed citations
11.
Dalm, Simone U., et al.. (2022). Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine. European Journal of Nuclear Medicine and Molecular Imaging. 49(13). 4616–4641. 29 indexed citations
12.
13.
Busstra, Martijn B., J. Fred Verzijlbergen, Mark Konijnenberg, et al.. (2021). GRPr Antagonist 68Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-Naïve Patients. Journal of Nuclear Medicine. 62(11). 1517–1523. 31 indexed citations
14.
Vliet, Nicole van, Simone U. Dalm, Erik de Blois, et al.. (2020). Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging. 48(5). 1339–1350. 65 indexed citations
15.
Tiel, Sandra T. van, Joost Haeck, Gabriela N. Doeswijk, et al.. (2018). In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer. Molecular Imaging and Biology. 20(6). 973–983. 14 indexed citations
16.
Dalm, Simone U., J. Fred Verzijlbergen, & Marion de Jong. (2017). Review: Receptor Targeted Nuclear Imaging of Breast Cancer. International Journal of Molecular Sciences. 18(2). 260–260. 27 indexed citations
17.
Sieuwerts, Anieta M., Willemijne A.M.E. Schrijver, Simone U. Dalm, et al.. (2017). Progressive APOBEC3B mRNA expression in distant breast cancer metastases. PLoS ONE. 12(1). e0171343–e0171343. 27 indexed citations
18.
Dalm, Simone U. & Marion de Jong. (2017). Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome?. EJNMMI Radiopharmacy and Chemistry. 2(1). 11–11. 3 indexed citations
19.
Dalm, Simone U., Willemijne A.M.E. Schrijver, Anieta M. Sieuwerts, et al.. (2017). Prospects of Targeting the Gastrin Releasing Peptide Receptor and Somatostatin Receptor 2 for Nuclear Imaging and Therapy in Metastatic Breast Cancer. PLoS ONE. 12(1). e0170536–e0170536. 10 indexed citations
20.
Dalm, Simone U., John W.M. Martens, Anieta M. Sieuwerts, et al.. (2015). In Vitro and In Vivo Application of Radiolabeled Gastrin-Releasing Peptide Receptor Ligands in Breast Cancer. Journal of Nuclear Medicine. 56(5). 752–757. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. Srinivasan Breakdown of academic impact, for papers by Maria‐Luisa Tamma Breakdown of academic impact, for papers by Mihaela Ginj Breakdown of academic impact, for papers by Erik Parker Breakdown of academic impact, for papers by Shaobo Yao Breakdown of academic impact, for papers by Jörg Schmitt Breakdown of academic impact, for papers by Thorsten Poethko Breakdown of academic impact, for papers by Buddy Setyono-Han Breakdown of academic impact, for papers by Aurélie Prignon Breakdown of academic impact, for papers by Zohreh Varasteh
Rankless by CCL
2026